18FDG, [18F]FLT, [18F]FAZA, and 11C-Methionine Are Suitable Tracers for the Diagnosis and In Vivo Follow-Up of the Efficacy of Chemotherapy by miniPET in Both Multidrug Resistant and Sensitive Human Gynecologic Tumor Xenografts

<table>Histopathological analysis of tumor xenografts. Autopsy images show the human ovarian (a) and human epidermoid carcinoma (f) tumor xenografts 25 and 16 days after tumor cell implantation, respectively. Microscopic images of H&amp;E staining ((b) A2780 Pgp−, (c) A2780AD Pgp+; (g) KB-3-1 Pgp−, (h) KB-V-1 Pgp+) and UIC2 mAb-DAB immunostaining ((d) A2780 Pgp−, (e) A2780AD Pgp+; (i) KB-3-1 Pgp−, (j) KB-V-1 Pgp+) of xenograft tumor sections. Bar: 50 μm; magnification ×200.</table>

BioMed Research International

fig1

Figure 1

Figure 1: 18FDG, [18F]FLT, [18F]FAZA, and 11C-Methionine Are Suitable Tracers for the Diagnosis and In Vivo Follow-Up of the Efficacy of Chemotherapy by miniPET in Both Multidrug Resistant and Sensitive Human Gynecologic Tumor Xenografts

Figure 1 | 18FDG, [18F]FLT, [18F]FAZA, and 11C-Methionine Are Suitable Tracers for the Diagnosis and In Vivo Follow-Up of the Efficacy of Chemotherapy by miniPET in Both Multidrug Resistant and Sensitive Human Gynecologic Tumor Xenografts 